Inform women of the potential risk of neural tube defects with dolutegravir and discuss the benefits and risks of continuing treatment if a woman plans pregnancy.
Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment
Monitor blood pressure at least weekly for 2 months from initiation and then monthly afterwards for the first year and periodically thereafter during treatment
New contraindication for patients with complete DPD deficiency due to risk of life-threatening toxicity.
Regulatory Alerts, Cancer, Oncology, Breast cancer, Gastrointestinal cancer, Head and neck cancer, Oncology Room
5-fluorouracil (intravenous), capecitabine, tegafur: DPD testing recommended before initiation to identify patients at increased risk of severe and fatal toxicity
Patients with complete or partial dihydropyrimidine dehydrogenase (DPD) deficiency are at increased risk of severe and fatal toxicity during treatment with these medicines.
Only for patients unsuccessfully treated with proton pump inhibitors.
For adults with confirmed carbapenem-resistant Enterobacteriaceae.